Here’s Why Bristol-Myers Squibb Co (BMY) Stock Is Soaring

January 13, 2015 12:30 PM

13 0

Bristol-Myers shares jumped 3% yesterday after a late-stage study on cancer drug Opdivo proved to be a success, leading to Deutsche Bank raising its price target on the company’s stock

Bristol-Myers Squibb Co (NYSE:BMY) shares rallied 3% to close at $62.18 apiece yesterday, hitting a new 52-week high, after a late-stage study on the company’s cancer drug Opdivo was successful in meeting its primary endpoint.

Read more

To category page